#1 Clinical Trials Search in Europe

Gandotinib

This article discusses the ongoing clinical trials of Gandotinib (LY2784544), a promising drug being studied for the treatment of myeloproliferative neoplasms (MPNs). These blood cancers include myelofibrosis, essential thrombocythemia, and polycythemia vera. The trials aim to assess the safety and effectiveness of Gandotinib in patients who have not responded well to other treatments or are intolerant to standard therapies.

Table of Contents

What is Gandotinib?

Gandotinib, also known by its research code LY2784544, is an investigational medication being developed to treat certain blood disorders[1]. It is currently undergoing clinical trials to evaluate its safety and effectiveness in patients with specific types of blood cancers.

What Conditions Does Gandotinib Treat?

Gandotinib is being studied for the treatment of a group of blood disorders called myeloproliferative neoplasms (MPNs). Specifically, it targets three conditions[1]:

  • Myelofibrosis (MF): A condition where scar tissue forms in the bone marrow, affecting normal blood cell production.
  • Essential Thrombocythemia (ET): A disorder characterized by the overproduction of platelets in the bone marrow.
  • Polycythemia Vera (PV): A condition where the body produces too many red blood cells.

These conditions are considered rare blood cancers that affect the way your body produces blood cells.

How Does Gandotinib Work?

While the exact mechanism of action is not fully described in the provided information, Gandotinib is likely designed to target specific genetic mutations or pathways involved in the development of myeloproliferative neoplasms. It may help regulate blood cell production and alleviate symptoms associated with these conditions.

Current Clinical Trial

Gandotinib is currently being evaluated in a Phase 2 clinical trial[1]. The main goal of this study is to assess how well Gandotinib works when given once daily to patients with myeloproliferative neoplasms. The researchers are particularly interested in measuring the objective response rate, which refers to the proportion of patients whose cancer shrinks or disappears after treatment.

Who is Eligible for the Trial?

The clinical trial has specific criteria for who can participate. Some key eligibility factors include[1]:

  • Being 18 years of age or older
  • Having a confirmed diagnosis of PV, ET, or MF
  • Having stopped previous treatments for MPNs for at least 14 days (with some exceptions)
  • Having adequate organ function
  • For some patients, having failed or being intolerant to standard therapies

There are also several factors that would exclude someone from participating, such as certain heart conditions, active infections, or recent major surgery.

How is Gandotinib Administered?

Gandotinib is taken orally in the form of capsules[1]. The maximum daily dose being studied is 120 mg. Patients must be able to swallow capsules to participate in the trial.

Potential Benefits of Gandotinib

While the full benefits of Gandotinib are still being studied, the researchers hope it will provide an effective treatment option for patients with myeloproliferative neoplasms. This is particularly important for patients who have not responded well to other treatments or cannot tolerate standard therapies[1].

Important Considerations

It’s crucial to remember that Gandotinib is still an investigational drug. This means:

  1. Its full safety profile and effectiveness are not yet established.
  2. It is not currently approved for general use outside of clinical trials.
  3. Participation in the clinical trial involves careful monitoring and follow-up with healthcare providers.

If you have a myeloproliferative neoplasm and are interested in learning more about Gandotinib or the clinical trial, it’s important to discuss this with your healthcare provider. They can help you understand if this might be an appropriate option for you and guide you through the process of potentially participating in the trial.

Aspect Details
Drug Name Gandotinib (LY2784544)
Trial Phase Phase 2
Conditions Studied Myeloproliferative neoplasms (MPNs): myelofibrosis, essential thrombocythemia, polycythemia vera
Primary Objective Assess activity of Gandotinib through objective response rate
Administration Oral capsules, once daily
Maximum Daily Dose 120 mg
Key Inclusion Criteria Age ≥18, MPN diagnosis, failed/intolerant to standard therapies, adequate organ function
Key Exclusion Criteria Recent enrollment in other trials, QTc interval >470 msec, serious preexisting medical conditions
Secondary Objectives Characterize toxicity profile, assess response criteria and efficacy, characterize PD-PHK

FAQ

  • What is Gandotinib? Gandotinib, also known as LY2784544, is an investigational drug being studied for the treatment of myeloproliferative neoplasms (MPNs), which are a group of blood cancers.
  • What types of blood cancers is Gandotinib being tested for? Gandotinib is being tested for myeloproliferative neoplasms (MPNs), specifically myelofibrosis, essential thrombocythemia, and polycythemia vera.
  • Who is eligible to participate in the Gandotinib clinical trial? Eligible participants must be at least 18 years old, have a diagnosis of one of the specified MPNs, and have either failed or been intolerant to standard therapies. They must also meet certain health criteria and be willing to follow study procedures.
  • How is Gandotinib administered in the clinical trial? Gandotinib is administered orally in capsule form once daily. The maximum daily dose in the trial is 120 mg.
  • What is the main goal of the Gandotinib clinical trial? The primary objective of the trial is to assess the activity of Gandotinib therapy, as measured by objective response rate, in patients with myeloproliferative neoplasms, including those who have not responded well to or have progressed on other treatments like ruxolitinib.

Ongoing Clinical Trials on Gandotinib

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Myeloproliferative neoplasms (MPNs): A group of blood cancers that cause the bone marrow to produce too many of certain types of blood cells.
  • Myelofibrosis: A type of MPN where scar tissue forms in the bone marrow, leading to decreased blood cell production.
  • Essential thrombocythemia: A type of MPN characterized by an overproduction of platelets in the bone marrow.
  • Polycythemia vera: A type of MPN where the body produces too many red blood cells.
  • JAK2 V617F mutation: A genetic mutation commonly found in patients with MPNs, which is used as a diagnostic marker and potential treatment target.
  • Objective response rate: A measure used in clinical trials to determine how well a treatment is working, based on the proportion of patients whose cancer shrinks or disappears after treatment.
  • Ruxolitinib: A medication used to treat certain myeloproliferative neoplasms, which some patients in the Gandotinib trial may have previously taken.
  • ECOG performance status: A scale used to assess how a patient's disease is progressing and how it affects their daily living abilities.
  • QTc interval: A measurement on an electrocardiogram that represents the time it takes for the heart's electrical system to recharge between beats.

References

  1. http://clinicaltrials.eu/trial/study-of-gandotinib-for-patients-with-myeloproliferative-neoplasms-myelofibrosis-essential-thrombocythemia-or-polycythemia-vera/